Source: Advanced Cell Technology, Inc.
Posted: March 20, 2007 8:33 am ET
Summary:
Advanced Cell Technology, Inc. announced that preclinical studies using human embryonic stem cells (hESCs) derived from its proprietary ACTcellerate technology (a means of accelerating the discovery of products from hESC) will be used as part of a study to determine if hESCs are safe and effective in animal models for heart attacks and heart failure. The studies will be funded under a $2.52 million grant awarded to University of California, San Francisco (UCSF) scientist Randall Lee, M.D, Ph.D., Associate Professor of Medicine, from the California Institute for Regenerative Medicine. The grant is for four years of study. CIRM, the governing body of Proposition 71, manages the $3 billion California initiative.
